US$ 23.24
bpc-157 human clinical trial evidence safety regulatory status trials review BPC-157 Research Peptide BPC-157: What you need to
Description
The medication significantly slows gastric emptying, which is central to its therapeutic mechanism but may potentially alter the normal digestive processes required for B12 liberation from food proteins and subsequent binding to intrinsic factor
Metformin users, common among type 2 diabetes patients who then add semaglutide, face a double hit since metformin independently reduces B12 absorption by 10-30% over long-term use

In multiple IRB-approved studies, patients showed an average 29% reduction after the first treatment

So if you block NO production with L-NAME, healing goes down
